EXAGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.38 USD | -1.43% |
|
-1.43% | -30.65% |
| Mar. 18 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M | MT |
Financials (USD)
| Sales 2024 * | 54.16M | Sales 2025 * | 62.91M | Capitalization | 23.79M |
|---|---|---|---|---|---|
| Net income 2024 * | -24M | Net income 2025 * | -19M | EV / Sales 2024 * | 0.44 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.38 x |
| P/E ratio 2024 * |
-1.01
x | P/E ratio 2025 * |
-1.33
x | Employees | 177 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Exagen Inc.
More recommendations
More press releases
| 1 day | -1.43% | ||
| 1 week | -1.43% | ||
| Current month | -13.21% | ||
| 1 month | -14.29% | ||
| 3 months | -28.50% | ||
| 6 months | -15.85% | ||
| Current year | -30.65% |
1 week
1.33
1.43
1 month
1.301.65
Current year
1.302.40
1 year
1.303.92
3 years
1.3017.98
5 years
1.3029.86
10 years
1.3029.86
| Managers | Title | Age | Since |
|---|---|---|---|
John Aballi
CEO | Chief Executive Officer | 39 | 22-10-16 |
Kamal Adawi
DFI | Director of Finance/CFO | 45 | 17-05-31 |
Ming-Chou Lee
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Robertson
BRD | Director/Board Member | 61 | 19-07-29 |
Paul Kim
BRD | Director/Board Member | 56 | 23-07-23 |
Wendy Johnson
BRD | Director/Board Member | 72 | 20-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.38 | -1.43% | 2,617 |
| 24-04-23 | 1.4 | 0.00% | 11,155 |
| 24-04-22 | 1.4 | +2.19% | 6,118 |
| 24-04-19 | 1.37 | -4.12% | 6,591 |
| 24-04-18 | 1.429 | +2.06% | 8,542 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotes
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.38
USD
Average target price
5.5
USD
Spread / Average Target
+298.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.65% | 24.13M | |
| -14.17% | 86.34B | |
| +17.86% | 84.49B | |
| +10.92% | 29.68B | |
| -8.51% | 17.5B | |
| -2.67% | 16.67B | |
| -0.24% | 15.18B | |
| -3.63% | 12.71B | |
| +2.63% | 12.53B | |
| -30.53% | 11.89B |
- Stock Market
- Equities
- XGN Stock
